Fig. 4.

The correlation between the methylation status of PRDM family members and patients with UCEC (UALCAN). Higher methylation levels are observed in PRDM1 A, PRDM2 B, MECOM C, PRDM7 G, PRDM10 J, PRDM11 K, PRDM15 O show low levels of methylation. PRDM5 E, PRDM8 H, PRDM9 I, PRDM12 L, PRDM13(M), PRDM14 N, and PRDM16 P exhibit higher levels of methylation, indicating their potential involvement in tumor development through epigenetic silencing. Conversely, no significant differences in methylation are found in PRDM4 D and PRDM6 F, suggesting their distinct roles in cancer progression. Statistical significance is represented by an asterisk (*p < 0.05, **p < 0.01, ***p < 0.001, NS: not significant), with a higher significance level indicating a more pronounced difference in methylation between normal and cancerous tissues